• Rifampin: From Mechanism to Assay Architecture

  2026-09-12

  Rifampin is a rifamycin antibiotic that enables precise bacterial transcription perturbation. This guide advances beyond routine workflows by showing how to connect molecular inhibition, exposure controls, resistance interpretation, and orthogonal assay design.

• Tyrothricin: A Membrane Assay Framework

  2026-09-11

  Tyrothricin is a peptide antibiotic mixture suited to mechanistic studies of microbial membrane injury. This article presents an assay-centered framework that connects membrane readouts with the experimental logic of recent trigeminal ganglion research without overstating translational relevance.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-11

  The reference study identifies CD44 as a functional metabolic dependency of IDH-mutant leukemia, linking adhesion signaling to pentose phosphate pathway activity, glycolytic suppression, NADPH production, and sustained R-2HG synthesis. Its isogenic genetic models and combination experiments support CD44 blockade as a mechanistic strategy to investigate resistance to mutant-IDH inhibition in acute myeloid leukemia.

• Amikacin and the New Logic of Resistance Research

  2026-09-10

  Amikacin (BAY416651) can do more than serve as an antimicrobial readout. Paired with carbapenemase localization, conjugation, mobile-element analysis, and strain typing, it helps translational researchers connect ribosomal action with the movement and expression of resistance in high-priority Enterobacterales.

• Cefoperazone Sodium Salt: Research Evidence

  2026-09-10

  Cefoperazone sodium salt is a broad-spectrum semisynthetic cephalosporin used in antibacterial, β-lactamase-resistance, and biliary tract infection research. Product data describe strong gram-negative coverage, high biliary distribution after intravenous administration, and practical DMSO and water solubility parameters.

• Haloprogin Research Workflows

  2026-09-09

  Haloprogin supports controlled studies of dermatophytes, Candida, and selected Gram-positive bacteria through matched MIC, MFC, formulation, and topical infection workflows. Its historical comparison with tolnaftate makes it especially useful for testing broader antimicrobial coverage and translating in vitro findings into animal-model designs.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-09-09

  Lutomski and colleagues developed a native top-down mass spectrometry workflow that releases membrane proteins and signaling complexes directly from retinal disc membranes, preserving links between proteoforms, lipid modifications, and ligand interactions. The study shows how this approach can resolve PDE6 off-target binding and reveal why protein lipidation may influence drug recognition in a native signaling environment.

• Vancomycin Workflows for Resistance Research

  2026-09-08

  Build more reproducible antibacterial assays with Vancomycin, from DMSO stock preparation to broth microdilution and MRSA-focused resistance studies. This workflow also shows how the reference study’s comparative design can improve controls, isolate handling, and interpretation without confusing temafloxacin findings with Vancomycin performance.

• MLKL Polymerization Drives Lysosomal Permeabilization

  2026-09-08

  The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a critical execution step in necroptosis. Using live-cell imaging, lysosomal tracking, genetic perturbation, and pharmacological inhibition, the authors show that cathepsin B release after lysosomal damage is a major driver of downstream cell death.

• Carbapenemase Gene Transmission in CREC

  2026-09-07

  This study integrates gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element analysis, and strain typing to clarify how carbapenemase-encoding genes circulate in carbapenem-resistant Enterobacter cloacae across hospitals in Guangdong. Its findings emphasize plasmid-associated blaNDM-1, frequent horizontal transfer, and the need to combine resistance phenotypes with molecular and epidemiological evidence when designing antimicrobial resistance research.

• Necrosulfonamide in MLKL Necroptosis Assays

  2026-09-07

  Necrosulfonamide provides a pathway-focused way to test whether membrane-disruptive MLKL activity drives injury after oxidative, ischemic, or chemically induced stress. This practical guide connects NSA dosing, p-MLKL localization, calcium-mitochondrial readouts, and troubleshooting for more decisive necroptosis assays.

• CDK4–4E-BP1 Control of Translation at Mitosis–G1

  2026-09-05

  Mitchell, Menon, and Garner identify CDK4 as a regulator of 4E-BP1 and show how this kinase supports cap-dependent translation during the transition from mitosis to G1. The work extends cell-cycle biology beyond CDK4–Rb signaling and provides a framework for interpreting translational control, mTOR inhibitor resistance, and cancer-relevant kinase crosstalk.

• Ceftazidime in Gram-Negative Resistance Research

  2026-09-04

  Ceftazidime combines strong activity against Pseudomonas aeruginosa with a practical phenotype layer for resistance studies. This workflow pairs susceptibility testing with plasmid localization, gene detection, conjugation, and strain typing to distinguish antibacterial activity from carbapenemase-driven dissemination.

• 3-Aminobenzamide: A PARP Biology Decision Guide

  2026-09-04

  3-Aminobenzamide (PARP-IN-1) is examined here as a mechanistic tool for separating PARP-dependent stress phenotypes from isoform-specific effects. This guide connects oxidative injury, vascular and renal models, and coronavirus macrodomain biology while defining practical controls and interpretation limits.

• Gepotidacin for Uncomplicated Urogenital Gonorrhea

  2026-09-03

  This phase 2 randomized study evaluated whether a single oral dose of the novel bacterial type II topoisomerase inhibitor gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infections. Both tested doses produced at least 95% microbiological eradication in the evaluable population, while treatment failures were associated with a common mutation and the highest observed gepotidacin MIC.

7988 records 1/533 page Next 12345 下5页 Last page